COX 2 inhibitors, traditional NSAIDs, and the heart -: Adverse event data from clinical trials must inform decision making

被引：36

作者：

Jüni, P

Reichenbach, S

Egger, M

机构：

[1] Univ Bern, Dept Social & Prevent Med, CH-3012 Bern, Switzerland

[2] Univ Hosp Bern, Dept Rheumatol, CH-3010 Bern, Switzerland

[3] Univ Bristol, MRC, Hlth Serv Res Collaborat, Dept Social Med, Bristol BS8 2PR, Avon, England

来源：

BMJ-BRITISH MEDICAL JOURNAL | 2005年 / 330卷 / 7504期

关键词：

D O I：

10.1136/bmj.330.7504.1342

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：1342 / 1343

页数：4

共 13 条

[1] Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial [J].

Bresalier, RS ;

Sandler, RS ;

Quan, H ;

Bolognese, JA ;

Oxenius, B ;

Horgan, K ;

Lines, C ;

Riddell, R ;

Morton, D ;

Lanas, A ;

Konstam, MA ;

Baron, JA .

NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (11) :1092-1102

[2] CALCIUM-CHANNEL BLOCKERS AND MYOCARDIAL-INFARCTION - A HYPOTHESIS FORMULATED BUT NOT YET TESTED [J].

BURING, JE ;

GLYNN, RJ ;

HENNEKENS, CH .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1995, 274 (08) :654-655

[3] Lessons from the withdrawal of rofecoxib - Patients would be safer if drug companies disclosed adverse events before licensing [J].

Dieppe, PA ;

Ebrahim, S ;

Martin, RM ;

Juni, P .

BRITISH MEDICAL JOURNAL, 2004, 329 (7471) :867-+

[4] Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial [J].

Farkouh, ME ;

Kirshner, H ;

Harrington, RA ;

Ruland, S ;

Verheugt, FW ;

Schnitzer, T ;

Burmester, GR ;

Mysler, E ;

Hochberg, MC ;

Doherty, M ;

Ehrsam, E ;

Gitton, X ;

Krammer, G ;

Mellein, B ;

Gimona, A ;

Matchaba, P ;

Hawkey, CJ ;

Chesebro, JH .

LANCET, 2004, 364 (9435) :675-684

[5]

Furberg CD, 2002, JAMA-J AM MED ASSOC, V288, P2981

[6] Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis [J].

Hippisley-Cox, J ;

Coupland, C .

BMJ-BRITISH MEDICAL JOURNAL, 2005, 330 (7504) :1366-1369

[7] Differences in outcomes of patients with congestive heart failure prescribed celecoxib, rofecoxib, or non-steroidal anti-inflammatory drugs: population based study [J].

Hudson, M ;

Richard, H ;

Pilote, L .

BMJ-BRITISH MEDICAL JOURNAL, 2005, 330 (7504) :1370-1373

[8] Better reporting of harms in randomized trials: An extension of the CONSORT statement [J].

Ioannidis, JPA ;

Evans, SJW ;

Gotzsche, PC ;

O'Neill, RT ;

Altman, DG ;

Schulz, K ;

Moher, D .

ANNALS OF INTERNAL MEDICINE, 2004, 141 (10) :781-788

[9] Risk of cardiovascular events and rofecoxib: cumulative meta-analysis [J].

Juni, P ;

Nartey, L ;

Reichenbach, S ;

Sterchi, R ;

Dieppe, PA ;

Egger, M .

LANCET, 2004, 364 (9450) :2021-2029

[10]

LU L, 21341 NDA

← 1 2 →